The latest clinical trials into novel AML therapies

The latest clinical trials into novel AML therapies

VJHemOnc

1 year
283 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses the new and exciting clinical trials that are currently underway for the treatment of acute myeloid leukemia (AML), including a Phase I study of isocitrate dehydrogenase (IDH) inhibitors in combination with induction chemotherapy, a Phase III study investigating low dose cytarabine and venetoclax, and the ADMIRAL study (NCT02421939) of the FLT3 inhibitor, gilteritnib, versus salvage chemotherapy in relapsed and refractory AML. Dr Stein also conveys his excitement about the QuANTUM-R trial (NCT02039726), which is investigating the effects of quizartinib monotherapy versus salvage chemotherapy on overall survival rates. This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.
Up Next Autoplay
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Category: Acute Myelogenous Leukemia
5 Views
Cancer-News 4 days
Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment
Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment
Category: Acute Myelogenous Leukemia
15 Views
Cancer-News 1 month
How to Manage MDS Patients who are Ineligible for Transplant
How to Manage MDS Patients who are Ineligible for Transplant
Category: Acute Myelogenous Leukemia
300 Views
obr 5 months
The Recent Wave of Approval in AML
The Recent Wave of Approval in AML
Category: Acute Myelogenous Leukemia
138 Views
obr 5 months
Updated Data on Gilteritinib in AML
Updated Data on Gilteritinib in AML
Category: Acute Myelogenous Leukemia
16 Views
obr 5 months
Latest Data on Uproleselan with Chemotherapy
Latest Data on Uproleselan with Chemotherapy
Category: Acute Myelogenous Leukemia
100 Views
obr 5 months
AML Case: A 54-year-old woman is in remission but MRD+
AML Case: A 54-year-old woman is in remission but MRD+
Category: Acute Myelogenous Leukemia
115 Views
imedex 6 months
Update: New Drugs for AML
Update: New Drugs for AML
Category: Acute Myelogenous Leukemia
177 Views
imedex 6 months
Hypomethylating Agents In Myeloid Disorders: Lower Doses Of Decitabine And Azacitidine Have Proven As Effective As Standard Dosing
Hypomethylating Agents In Myeloid Disorders: Lower Doses Of Decitabine And Azacitidine Have Proven As Effective As Standard Dosing
Category: Acute Myelogenous Leukemia
100 Views
Annual-Meeting 6 months
Should We Check If The Donor Has A Mutation: Depends On The Type Of Mutation, Not Every Mutation Is The Same
Should We Check If The Donor Has A Mutation: Depends On The Type Of Mutation, Not Every Mutation Is The Same
Category: Acute Myelogenous Leukemia
107 Views
Annual-Meeting 6 months